The patent entitled ‘8-Hydroxyquinoline derivatives’ also covers pharmaceutical compositions containing PBT2 and selected 8-hydroxyquinoline compounds and the use of the compounds for the treatment of Alzheimer’s disease.
Prana executive chairman Geoffrey Kempler said this decision by the Japanese Office to grant a claim to PBT2 completes a suite of core patent rights protecting this asset in key markets including the US, Europe, Japan and Australia, further bolstering their commercialization plans in both Huntington’s and Alzheimer’s disease.